EDIT Editas Medicine Inc.

Editas Medicine to Participate in Upcoming Investor Conferences

Editas Medicine to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that management will participate in the following upcoming investor conferences in November and December:

  • Guggenheim’s Inaugural Healthcare Innovation Conference

    Format: Fireside Chat

    Date: Tuesday, November 12

    Time: 4:00 p.m. ET

    Location: Boston, MA
  • Stifel 2024 Healthcare Conference

    Format: Fireside Chat

    Date: Tuesday, November 19

    Time: 1:50 p.m. ET

    Location: New York, NY
  • 7th Annual Evercore ISI HealthCONx Conference

    Format: Fireside Chat

    Date: Tuesday, December 3

    Time: 1:20 p.m. ET

    Location: Coral Gables, FL

To access the live webcasts of Editas Medicine’s presentations, please visit the “Investors” section of the Company’s website at . An archived replay will be available for approximately 30 days following each event.

About Editas Medicine

As a clinical-stage gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit .



Media and Investor Contact:
Cristi Barnett
(617) 401-0113
EN
06/11/2024

Underlying

EDITEditas Medicine Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Editas Medicine Inc.

 PRESS RELEASE
Free
EDIT Editas Medicine...

Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare C...

Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference CAMBRIDGE, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced that the Company’s President and CEO Gilmore O’Neill, M.B., M.M.Sc., will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, 11:15 a.m. PT / 2:15 p.m. ET in San Francisco, CA. A of the presentation will be available on the “Investors” section of the Editas Medicine website at . An archived replay will be available on the website fo...

January 6, 2025 1 EN
 PRESS RELEASE
Free
EDIT Editas Medicine...

Editas Medicine Announces Strategic Transition to in vivo Gene Editing...

Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years Focus on in vivo CRISPR-edited medicines based on Editas researchers’ recent scientific progress in multiple tissues: Achieved pre-clinical in vivo proof of concept of high level HBG1/2 promoter editing and HbF induction in a humanized mouse model for treatment of sickle cell disease and beta thalassemia with a single dose of an HSC-targeted lipid nanoparticle (tLNP) formulationAchieved in vivo proof of concept of high efficiency editing in...

December 12, 2024 1 EN
 PRESS RELEASE
Free
EDIT Editas Medicine...

Editas Medicine Reports Updated Clinical Data from the RUBY Trial of R...

Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting Poster presentation at ASH on Monday, December 9 at 6:00 p.m. PT / 9:00 p.m. ET CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, will present updated safety and efficacy data in 28 patients living with severe sickle cell disease (SCD) treated with renizgamglogene autogedtemcel (reni-cel; formerly known as EDIT-301) in the Phase 1/2/3 RUBY...

December 9, 2024 1 EN
 PRESS RELEASE
Free
EDIT Editas Medicine...

Editas Medicine to Participate in Upcoming Investor Conferences

Editas Medicine to Participate in Upcoming Investor Conferences CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that management will participate in the following upcoming investor conferences in November and December: Guggenheim’s Inaugural Healthcare Innovation ConferenceFormat: Fireside ChatDate: Tuesday, November 12Time: 4:00 p.m. ETLocation: Boston, MA Stifel 2024 Healthcare ConferenceFormat: Fireside ChatDate: Tuesday, November 19Time: 1:50 p.m. ETLocation: New York, NY 7th Annual Ever...

November 6, 2024 1 EN
 PRESS RELEASE
Free
EDIT Editas Medicine...

Editas Medicine Announces Third Quarter 2024 Results and Business Upda...

Editas Medicine Announces Third Quarter 2024 Results and Business Updates Achieved in vivo preclinical proof of concept of HBG1/2 editing in hematopoietic stem and progenitor cells (HSPCs) using Editas Medicine’s proprietary targeted LNP in a key step to developing a novel in vivo treatment for sickle cell disease and beta thalassemia On track to share additional clinical and patient reported outcomes data from 28 patients in the RUBY trial for sickle cell disease at the American Society of Hematology (ASH) Annual Meeting and Exposition in December Company to provide an update on its in v...

November 4, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch